




# STRATÉGIE D'ACCÉLÉRATION MALADIES INFECTIEUSES ÉMERGENTES (MIE) ET MENACES NRBC (MN) 2022

## VOLET INNOVATION MESURE 6

**OPEN-ReMIE**



Réseau Opérationnel National de Recherche pour les Maladies Infectieuses  
Émergentes

National Operational Research network for Emerging Infectious Diseases

Project leader : Florence ADER


Project co-leader : Karine LACOMBE

Project manager ANRS-MIE : Auriane MERELLE

LE SECRETAIRE GENERAL  
POUR L'INVESTISSEMENT



STRATÉGIE D'ACCÉLÉRATION MALADIES  
INFECTIEUSES ÉMERGENTES (MIE) ET  
MENACES NRBC (MN)  
2022  
VOLET INNOVATION  
MESURE 6



DISCOVERY



OPEN-ReMIE  
10 M€ - 5 ans

Aussi:  
EMERGEN 2.0  
I-REIVAC Emergence  
OBEPINE+



Programme  
Horizon 2024



PROACT EU  
RESPONSE

KOM 29-30/01/2025



# « The next pandemic is not a matter of if, but rather when... »

Accélérer la **recherche clinique interventionnelle** avec sponsors académiques ou industriels  
Par des reseaux nationaux de recherche pour la preparation “**preparedness**” et la réponse aux maladies infectieuses émergentes épidémiques et à potentiel pandémique




Interventions thérapeutiques et/ou immunomodulatrices en milieu hospitalier = OPEN-ReMIE



Porter cet effort en lien et synergie avec les réseaux nationaux et internationaux de recherche clinique



Consolider et enrichir ce réseau dans la durée “**sustainability**” et le transmettre aux générations futures de professionnels de santé formés au risque émergent biologique



## OPEN-ReMIE development team

### WEEKLY MEETING (or MORE if crisis)

#### Operational core team

- Coordinate and oversee tasks of the WPs on a daily basis
- Composition:
  - Project coordinators (FA, KL)
  - WP leaders
  - Network management officer, quality management officer, lab network coordinators
- Point of entry

## OPEN-ReMIE Scientific Committee

### MONTHLY MEETING (or more if crisis)

#### Overall supervision of the network

- Deciding body
- Voting and non-voting members
- Participation in or initiate a new clinical trial or add a sub-protocol

#### International platform trials

(EU-RESPONSE, STRIVE, REMAP-CAP, RECOVERY)

#### Agencies

ANRS-MIE, ANSM, EMA, CNIL, F-CRIN

#### R&D Innovations

#### Civil society think tanks

|                   |                                                                        |
|-------------------|------------------------------------------------------------------------|
| <b>WP1 leader</b> | <b>WP1: Regulatory procedures and sponsorship</b>                      |
| WP2 leader        | WP2: Clinical sites network                                            |
| WP3 leader        | WP3: Methodology and management centers                                |
| WP4 leader        | WP4: Laboratory network and biocollection biobanking                   |
| WP5 leader        | WP5: Investigational drug supply and use, pharmacovigilance and safety |
| WP6 leader        | WP6: Training, Communication, valorization and dissemination           |





- Charte OPEN-ReMIE
- Aspects réglementaires et promotion (responsabilité de la recherche)
- Plan d'action : gestion du risque, simplification des procédures, fast-track/accélération (?)
- Contrats type
- Interface avec les agences de régulation : ANSM, CNIL,...
- Interface avec toutes les parties prenantes

**CTIS / EU Regulatory procedures**

|                   |                                                                        |
|-------------------|------------------------------------------------------------------------|
| <b>WP1 leader</b> | <b>WP1: Regulatory procedures and sponsorship</b>                      |
| <b>WP2 leader</b> | <b>WP2: Clinical sites network</b>                                     |
| WP3 leader        | WP3: Methodology and management centers                                |
| WP4 leader        | WP4: Laboratory network and biocollection biobanking                   |
| WP5 leader        | WP5: Investigational drug supply and use, pharmacovigilance and safety |
| WP6 leader        | WP6: Training, Communication, valorization and dissemination           |



- MIT/MIR
- Sites de 1<sup>er</sup> cercle et 2<sup>ème</sup> cercle
- Audit des sites, interface avec DRCI locales et contrats types standards
- Production de protocoles génériques (WP3)
- Catalogue de variables cliniques et biologiques (CRF) (WP3)
- Interface avec les industriels du médicaments (start up, PME, internationaux) + recherche académique



**RENARCI**

|                   |                                                                        |
|-------------------|------------------------------------------------------------------------|
| <b>WP1 leader</b> | <b>WP1: Regulatory procedures and sponsorship</b>                      |
| <b>WP2 leader</b> | <b>WP2: Clinical sites network</b>                                     |
| <b>WP3 leader</b> | <b>WP3: Methodology and management centers</b>                         |
| WP4 leader        | WP4: Laboratory network and biocollection biobanking                   |
| WP5 leader        | WP5: Investigational drug supply and use, pharmacovigilance and safety |
| WP6 leader        | WP6: Training, Communication, valorization and dissemination           |



- 5 CMG aux compétences complémentaires
- Alignement avec EU
- Production de protocoles génériques (WP2)
- Stratification des variables : critiques, standard, accessoires, étendues (CRF) (WP2)
- Développement autres méthodologies : méta-analyses, essais émulsés, bras synthétiques,...
- Data management (stockage, transfert, analyse)
- Interopérabilité des données
- Plan de monitoring

**I-REIVAC-EMERGENCE**



|                   |                                                                        |
|-------------------|------------------------------------------------------------------------|
| <b>WP1 leader</b> | <b>WP1: Regulatory procedures and sponsorship</b>                      |
| <b>WP2 leader</b> | <b>WP2: Clinical sites network</b>                                     |
| <b>WP3 leader</b> | <b>WP3: Methodology and management centers</b>                         |
| <b>WP4 leader</b> | <b>WP4: Laboratory network and biocollection biobanking</b>            |
| WP5 leader        | WP5: Investigational drug supply and use, pharmacovigilance and safety |
| WP6 leader        | WP6: Training, Communication, valorization and dissemination           |



- Catalogue de prestations -----> microbiologique, pharmacologique, immunologique
- Centre de ressource biologique (CRB)

**EMERGEN 2.0**  
**I-REIVAC-EMERGENCE**  
**OBEPINE<sup>+</sup>**

|                   |                                                                        |
|-------------------|------------------------------------------------------------------------|
| <b>WP1 leader</b> | <b>WP1: Regulatory procedures and sponsorship</b>                      |
| <b>WP2 leader</b> | <b>WP2: Clinical sites network</b>                                     |
| <b>WP3 leader</b> | <b>WP3: Methodology and management centers</b>                         |
| <b>WP4 leader</b> | <b>WP4: Laboratory network and biocollection biobanking</b>            |
| WP5 leader        | WP5: Investigational drug supply and use, pharmacovigilance and safety |
| WP6 leader        | WP6: Training, Communication, valorization and dissemination           |



- Catalogue de prestations -----> microbiologique, pharmacologique, immunologique
- Centre de ressource biologique (CRB)

**EMERGEN 2.0**  
**I-REIVAC-EMERGENCE**  
**OBEPINE<sup>+</sup>**

|                   |                                                                               |
|-------------------|-------------------------------------------------------------------------------|
| <b>WP1 leader</b> | <b>WP1: Regulatory procedures and sponsorship</b>                             |
| <b>WP2 leader</b> | <b>WP2: Clinical sites network</b>                                            |
| <b>WP3 leader</b> | <b>WP3: Methodology and management centers</b>                                |
| <b>WP4 leader</b> | <b>WP4: Laboratory network and biocollection biobanking</b>                   |
| <b>WP5 leader</b> | <b>WP5: Investigational drug supply and use, pharmacovigilance and safety</b> |
| <b>WP6 leader</b> | <b>WP6: Training, Communication, valorization and dissemination</b>           |

- Circuit du médicament et ses particularités -----> gestion des stocks, mobilisation, délivrance.
- Pharmacovigilance ANRS-MIE : procédures, organisation sécurité,
- Connexion agences : ANSM, EMA, FDA

**I-REIVAC-EMERGENCE**

|                       |                                                                               |
|-----------------------|-------------------------------------------------------------------------------|
| <b>WP1<br/>leader</b> | <b>WP1: Regulatory procedures and sponsorship</b>                             |
| <b>WP2<br/>leader</b> | <b>WP2: Clinical sites network</b>                                            |
| <b>WP3<br/>leader</b> | <b>WP3: Methodology and management centers</b>                                |
| <b>WP4<br/>leader</b> | <b>WP4: Laboratory network and biocollection biobanking</b>                   |
| <b>WP5<br/>leader</b> | <b>WP5: Investigational drug supply and use, pharmacovigilance and safety</b> |
| <b>WP6<br/>leader</b> | <b>WP6: Training, Communication, valorization and dissemination</b>           |



- Site web pour communication et dissémination
- Volet SHS/milieux associatifs et académiques: société civile et recherche clinique interventionnelle en temps de crise, lutte contre la désinformation et l'infodémie, cyberharcèlement, discrimination de genre, influence des réseaux sociaux.
- Education aux stratégies de communication

## Governance

### SAEB

Scientific and Ethics Advisory Board

### International platform trials

(EU-RESPONSE, STRIVE, REMAP-CAP, RECOVERY)

### Agencies

ANRS-MIE, ANSM, EMA, CNIL, F-CRIN

### R&D Innovations

### Civil society think tanks

OPEN-ReMIE Scientific Committee

OPEN-ReMIE core development team

WP1 leader

**WP1:** Regulatory procedures and sponsorship

CTIS / EU Regulatory procedures

WP2 leader

**WP2:** Clinical sites network

RENARCI

WP3 leader

**WP3:** Methodology and management centers

I-REIVAC-EMERGENCE

WP4 leader

**WP4:** Laboratory network and biocollection biobanking

EMERGEN 2.0  
I-REIVAC-EMERGENCE  
OBEPINE<sup>+</sup>

WP5 leader

**WP5:** Investigational drug supply and use, pharmacovigilance and safety

I-REIVAC-EMERGENCE


WP6 leader

**WP6:** Training, Communication, valorization and dissemination



**PROACT EU  
RESPONSE**

# Perspectives et connexions internationales



**Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE)**



# PROACT EU-Response

European PROactive Adaptive Clinical Trials network

Pr Karine Lacombe, Sorbonne Université  
AP-HP, St Antoine Hospital, Paris - France

# Building upon an existing network



**European Research and Preparedness Network for Pandemics  
and Emerging Infectious Diseases**

W1: Expand, organize and **conduct the DisCoVeRy clinical trial** in EU member states and associated countries.

W2: Build a multinational, European multi-arm **COVID-19 Adaptive Platform Trial** beyond the present DisCoVeRy partners and beyond the current protocol to provide a modular trial framework enabling most if not all European hospitals to participate at their preferred level of commitment to the new Adaptive Platform Trial



# Some results of EU-Response

## Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials

Alain Amstutz\*, Benjamin Speich\*, France Mentré, Corina Silvia Rueegg, Drifa Belhadi, Lambert Assoumou, Charles Burdet, Srinivas Murthy, Lori Elizabeth Dodd, Yeming Wang, Kari A O Tikkinen, Florence Ader, Maya Hites, Maude Bouscambert, Mary Anne Traubad, Mike Fralick, Todd C Lee, Ruxandra Pinto, Andreas Barratt-Due, Fridtjof Lund-Johansen, Fredrik Müller, Olli P O Nevalainen, Bin Cao, Tyler Bonnet, Alexandra Griessbach, Ala Taji Heravi, Christof Schönenberger, Perrine Janiaud, Laura Werlen, Soheila Aghlmandi, Stefan Schandelmaier, Yazdan Yazdanpanah, Dominique Costagliola, Inge Christoffer Olsen, Matthias Briel

*Lancet Respir Med* 2023;  
11: 453–64

Published Online  
February 21, 2023  
[https://doi.org/10.1016/S2213-2600\(22\)00528-8](https://doi.org/10.1016/S2213-2600(22)00528-8)

*Clinical Microbiology and Infection* 28 (2022) 1–5



Contents lists available at ScienceDirect

Clinical Microbiology and Infection

journal homepage: [www.clinicalmicrobiologyandinfection.com](http://www.clinicalmicrobiologyandinfection.com)

Commentary

Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group

*Journal of Infection* 88 (2024) 106120



Contents lists available at ScienceDirect

Journal of Infection

journal homepage: [www.elsevier.com/locate/jinf](http://www.elsevier.com/locate/jinf)

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial

Treiseid et al. *Critical Care* (2023) 27:9  
<https://doi.org/10.1186/s13054-022-04205-8>

Critical Care

RESEARCH

Open Access

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial



*Clinical Microbiology and Infection* 28 (2022) 1293–1296



Contents lists available at ScienceDirect

Clinical Microbiology and Infection

journal homepage: [www.clinicalmicrobiologyandinfection.com](http://www.clinicalmicrobiologyandinfection.com)



Letter to the Editor

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon- $\beta$ -1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results

Florence Ader\*, The DisCoVeRy Study Group

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial



*Lancet Infect Dis* 2022;  
22: 209–21

Published Online  
September 14, 2021  
[https://doi.org/10.1016/S1473-3099\(21\)00485-0](https://doi.org/10.1016/S1473-3099(21)00485-0)

Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Drifa Belhadi, Alpha Diallo, Minh-Patrick Lê, Gilles Peytavin, Thérèse Staub, Richard Greil, Jérémie Guedj, Jose-Artur Paiva, Dominique Costagliola, Yazdan Yazdanpanah, Charles Burdet\*, France Mentré\*, and the DisCoVeRy Study Group

# Brief summary of the PROACT EU-Response project

- **Overarching objective:** prepare Europe for future pandemics by strengthening upon existing networks of experts and civil society focused on clinical therapeutic platform trials within hospital inpatient settings across Europe.
  - ***expand a solid network of clinical centres across Europe*** that will implement a clinical trial assessing a syndromic approach for respiratory viral infections
  - ***strengthen a laboratory network*** to identify pathogens and biomarkers of disease monitoring for routine surveillance;
  - ***support a network of methodologists and trialists*** who will ensure the trials' logistical and methodological aspects;
  - ***initiate a network of professionals to work on preparedness tools*** to ensure a smooth pivot from inter-pandemic to the pandemic period in case of an outbreak;
  - ***build a network of social science researchers*** who will provide nuanced understanding of the social contexts;
  - ***establish a community group to work on activities that will empower patients and citizens*** in Europe regarding their own health and educate them about science and health issues.

# Partners & countries across europe

❑ 25 partners

❑ 11 countries

❑ Networks:

❑ Clinical: 31 countries

❑ 9 virological centers


❑ 5 methodology teams

❑ 4 implementation  
science teams


| N° | Participant organisation name                               | Country     |
|----|-------------------------------------------------------------|-------------|
| 1  | INSERM - ANRS                                               | France      |
| 2  | SORBONNE UNIVERSITE (Affiliated Entity)                     | France      |
| 3  | OSLO UNIVERSITETSSYKEHUS HF                                 | Norway      |
| 4  | SERVICIO MADRILENO DE SALUD                                 | Spain       |
| 5  | UNIVERSITE LIBRE DE BRUXELLES                               | Belgium     |
| 6  | UNIVERSITA DEGLI STUDI DI VERONA                            | Italy       |
| 7  | UNIVERSITY COLLEGE LONDON                                   | UK          |
| 8  | UNIVERSITY COLLEGE DUBLIN                                   | Ireland     |
| 9  | ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK     | France      |
| 10 | HOSPICES CIVILS DE LYON                                     | France      |
| 11 | BIOMERIEUX SA                                               | France      |
| 12 | ASSISTANCE PUBLIQUE HOPITAUX DE PARIS                       | France      |
| 13 | FORUM DES PATIENTS EUROPEENS                                | Belgium     |
| 14 | COLLECTIF NO FAKEMED                                        | France      |
| 15 | Vaccination et Lien Social                                  | France      |
| 16 | LES MARKABIENS                                              | France      |
| 17 | UNIVERSITY OF GALWAY                                        | Ireland     |
| 18 | INSERM TRANSFERT SA                                         | France      |
| 19 | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE                | France      |
| 20 | UNIVERSITEIT ANTWERPEN                                      | Belgium     |
| 21 | UNIVERSITY OF LANCASTER                                     | UK          |
| 22 | UNIVERSITY OF BRISTOL                                       | UK          |
| 23 | MEDIZINISCHE UNIVERSITAET WIEN                              | Austria     |
| 24 | STICHTING NEDERLANDSE WETENSCHAPPELIJK ONDERZOEK INSTITUTEN | Netherlands |
| 25 | UNIVERSITAT BASEL (Associated Partner)                      | Switzerland |

# Overall Work Plan: Clinical Trial Network and Clinical Trials

## Core Clinical Trial Network



## Expanded Clinical Trial Network



Drug 1 – Flu A/B, HMNV, CoV  
Drug 2 – Flu A/B, CoV  
Drug 3 – RSV, CoV  
Drug 4 - RSV

Inpatient with a Viral Respiratory Tract Infection

Diagnostic Test

Influenza A/B

RSV

Human Metapneumovirus

Coronavirus

Randomisation

Drug 1  
Drug 2  
SOC

Drug 3  
Drug 4  
SOC

Drug 1  
SOC

Drug 1  
Drug 2  
Drug 3  
SOC

Outcome & Safety

## In summary

- The PROACT EU-Response project is an ambitious programme that aims to achieve EU objectives for tackling diseases and reducing disease burden across the continent.
- It specifically responds to calls for ‘a resilient EU prepared for emerging threats’ and the need to address major societal challenges linked to the Commission’s political priorities such as preparedness and response to and surveillance of health threats and epidemics.